Article

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

Unité de Biologie Cellulaire, Hopital Saint-Louis, Assistance Publique-Hôpitaux de Paris, 75010 Paris, France.
Leukemia research (impact factor: 2.36). 02/2009; 33(9):1178-82. DOI:10.1016/j.leukres.2008.12.010 pp.1178-82
Source: PubMed

ABSTRACT 10-20% of APL patients relapse and the challenge remains to early identify these patients to improve survival rate. We report PML-RARalpha transcript detection by RQ-PCR in 260 consecutive APL patients (n = 970 samples). 223 patients with samples of sufficient RNA quality to demonstrate they reached molecular remission were monitored for MRD. During follow-up, 38 of these patients were tested positive for PML-RARalpha mRNA. 13 out of the 38 patients (34%) effectively developed hematological relapse. In the first positive sample, specific PML-RARalpha NCN thresholds over which, or under which, patients could effectively be predicted to relapse or not, were identified and subsequently validated in a second cohort.

0 0
 · 
0 Bookmarks
 · 
33 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

260 consecutive APL patients
 
38 patients
 
APL patients relapse
 
first positive sample
 
molecular remission
 
patients
 
RQ-PCR
 
second cohort
 
specific PML-RARalpha NCN thresholds
 
sufficient RNA quality
 
survival rate
 
validated